Reanalysis of the SIMPLIFY 1 and 2 trials data indicates MMB is effective in JAKi-naïve patients and in second line therapy to RUX, providing benefits of reducing enlarged spleens, improving myelofibrosis-related symptoms, and increasing transfusion independence in patient at risk for thrombocytopenia from the underlying disease and RUX therapy. Accordingly, methods of treating myeloproliferative neoplasms (MPN) such as myelofibrosis are described. The methods can include administering a therapeutically effective amount of momelotinib or a pharmaceutically acceptable salt thereof to a subject identified as having (i) myelofibrosis and (ii) a platelet count of less than 150 x 109/L. Also described are methods including administering to a subject with myelofibrosis a therapeutically effective stable dose of momelotinib or a pharmaceutically acceptable salt thereof, for a period of a plurality of weeks, where the subject is assessed as maintaining a platelet count above a predetermined threshold platelet count during the period.對SIMPLIFY 1及2試驗資料之重新分析表明，MMB對於未用JAKi治療的患者及作為RUX之二線療法的患者有效，在處於患來自潛在疾病及RUX療法之血小板減少症之風險下的患者中提供減少脾臟腫大、改善骨髓纖維化相關症狀及增加輸血獨立性的益處。因此，描述了治療骨髓增生性贅瘤(MPN)，諸如骨髓纖維化之方法。所述方法可包含向鑑別為具有(i)骨髓纖維化及(ii)小於150×109/L之血小板計數的個體投予治療有效量之莫羅替尼或其醫藥學上可接受之鹽。亦描述了包含持續多週之時段向患有骨髓纖維化之個體投予治療有效穩定劑量之莫羅替尼或其醫藥學上可接受之鹽的方法，其中所述個體係評估為在所述時段期間維持血小板計數高於預定臨限值血小板計數。
